Beneficial Effects Of Probiotics Research Articles

Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis

AimsTo systematically review evidence of probiotic interventions against type 2 diabetes mellitus (T2DM) and analyse the effects of probiotics on glycaemic control among T2DM patients. MethodsElectronic search using five electronic databases was performed until October 2015. Relevant studies were identified, extracted and assessed for risk of bias. The primary outcomes of this review were glycated haemoglobin (HbA1c) and fasting blood glucose (FBG). Fasting plasma insulin, homeostasis model assessment-insulin resistance, C-reactive protein, interleukin-6 and malondialdehyde, were identified as the secondary outcomes. Mean differences (MD) between probiotics and control groups for all outcomes were pooled using either Fixed- or Random-Effect Model. Statistical heterogeneity was assessed using I2 and Chi2 tests. ResultsSix randomised controlled trials (RCTs) were included in the systematic review, whereas only five were included in meta-analysis. Most RCTs were presented with low or unclear risk of bias. When compared to placebo, FBG was significantly lower with probiotic consumption (MD=−0.98mmol/L; 95% CI: −1.17, 0.78, p<0.00001), with moderate but insignificant heterogeneity noted. Insignificant changes between the groups were also noted for HbA1c and other secondary outcomes. ConclusionsA moderate hypoglycaemic effect of probiotics, with a significantly lower FBG was noted. Findings on HbA1c, anti-inflammatory and anti-oxidative effects of probiotics in the clinical setting, however, remain inconsistent. The findings imply the need for well-designed clinical studies to further assess the potential beneficial effects of probiotics in management of T2DM.

Integrated control of fish metabolism, wellbeing and reproduction: The role of probiotic

In the last decades, attempts to sustain an environmental friendly aquaculture have encouraged the use of beneficial bacterial, including probiotics, as feed enrichment. The use of probiotics has been extended far beyond finfish aquaculture, since they have been added to experimental and/or commercial diets formulated for invertebrates including Crustaceans, molluscs, echinoderms. The results so far obtained largely demonstrated beneficial effects of probiotics on fish growth, digestive function, immune system modulation, stress resistance and fecundity. Many studies demonstrated the potentiality of probiotic administration to elevate the fish innate defense mechanisms, hence improving survival following exposure to a number of pathogens. Benefits are driven, at least in part, by the modulation of the host microbiota. Probiotic “colonization” is the first key process responsible for increasing welfare.The review will summarize the effects of microbiota changes on welfare, growth and reproduction of both ornamental and commercial species. Reproduction is an energy-costly process that can be successfully faced only when sufficient energy stores are available. Particular emphasis will be given to the effect of probiotics on the interplay between metabolism and reproduction. A number of central energy sensors, hypothalamic neuropeptides, and several peripheral molecular mediators have been implicated in the regulation of the delicate interaction connecting the two processes.The last part of the review condenses recent findings regarding the positive effects of probiotic administration on fish gonads, which deeply support their role towards reproduction, mainly achieved on zebrafish. Indeed, the results presented scientifically support and strongly encourage the large scale use of probiotics in aquaculture practices, suggesting avoidance of pharmaceuticals use. If that becomes well established, a better quality, both health- and environment-wise, could be achieved and supplied to consumers. Statement of relevanceProbiotic improvement of growth, wellbeing and reproduction.

Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study.

Data has emerged on possible beneficial effects of probiotics in respiratory tract viral infections, but it is unclear if the promising positive effects evidenced are due to a reduced viral load during infections. The aims of this work were to investigate the effect of peroral probiotic Lactobacillus rhamnosus GG (American Type Culture Collection [ATCC], Accession No. 53103) consumption on human rhinovirus (HRV) load in nasopharyngeal lavage samples in experimental HRV infection, and to correlate viral load to clinical symptoms. Intranasal HRV A39 inoculation was performed on 59 adults, who had consumed juice enriched with live or heat-inactivated L. rhamnosus GG or control juice for 3 weeks prior to inoculation in a randomized, controlled, pilot trial setting. Nasopharyngeal lavage samples and symptom data were analyzed on day 0 before inoculation, and on days 2 and 5. Samples were subjected to quantitative HRV detection by polymerase chain reaction (PCR). Before inoculation 9 of 59 (15%) samples presented with another HRV strain than the studied A39. There was a tendency toward the lowest HRV loads in the L. rhamnosus GG groups and the highest in placebo group (log10 copies/mL, 95% confidence interval [CI], 6.20 [5.18 to 7.40] in live, 6.30 [4.91 to 7.08] in inactivated L. rhamnosus GG, and 7.25 [5.81 to 7.52] in placebo group, p = 0.57 in day 2) in the wild-type excluded population. The HRV load positively correlated with the symptom scores on days 2 and 5 (correlation coefficient 0.61 [p < 0.001] and 0.28 [p = 0.034], respectively). Results did not show statistical differences in viral loads in subjects using L. rhamnosus GG when compared to placebo. HRV load positively correlated with the total symptom scores.

Probiotics as Antifungals in Mucosal Candidiasis.

Candidais an opportunistic pathogen that causes mucosal and deep systemic candidiasis. The emergence of drug resistance and the side effects of currently available antifungals have restricted their use as long-term prophylactic agents for candidal infections. Given this scenario, probiotics have been suggested as a useful alternative for the management of candidiasis. We analyzed the available data on the efficacy of probiotics in candidal colonization of host surfaces. A number of well-controlled studies indicate that probiotics, particularly lactobacilli, suppressCandidagrowth and biofilm development in vitro.A few clinical trials have also shown the beneficial effects of probiotics in reducing oral, vaginal, and enteric colonization byCandida; alleviation of clinical signs and symptoms; and, in some cases, reducing the incidence of invasive fungal infection in critically ill patients. Probiotics may serve in the future as a worthy ally in the battle against chronic mucosal candidal infections.

Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer.

Chronic intestinal inflammation alters host physiology and could lead to colorectal cancer (CRC). We have previously reported beneficial effects of the probiotic strain of Lactobacillus casei BL23 in different murine models of intestinal inflammation. In addition, there is an emerging interest on the potential beneficial effects of probiotics to treat CRC. We thus explored whether L. casei BL23 displays protective effects on CRC. Mice were subcutaneously injected with 1,2-dimethylhydrazine (DMH) weekly during 10weeks and orally administered with L. casei BL23 in the drinking water until the 10th week. Multiple plaque lesions in the large intestine were observed macroscopically and counted and intestinal tissues were also histologically analyzed. Finally, T-cell populations and cytokine production were evaluated after co-incubation of L. casei BL23 with spleen cells from non-treated mice to determine the immuno-modulatory effects of this bacterium. Our results show that oral treatment with this probiotic bacterium modulates host immune responses and significantly protect mice against DMH-induced CRC. This protection may be associated with the modulation of regulatory T-cells towards a Th17-biased immune response accompanied by the expression of regulatorycytokines (IL-6, IL-17, IL-10 and TGF-β), as demonstrated in L. casei BL23-treated splenocytes, but also with the colonic expression of IL-22 observed in vivo on L. casei BL23-treated mice; suggesting the induction of a fine-tune Th17-biased response. Altogether our results reveal the high potential of L. casei BL23 to treat CRC and opens new frontiers for the study of immunomodulatory functions of probiotics.

Biochemical Characterization of Probiotics Available in Bangladesh

The pervasive beneficial effects of probiotics are important for the maintenance of mammalian homeostasis. The probiotic products are consumed by people in their various forms available in Bangladesh. In this context, this study is taken into consideration to identify and characterize bacteria to confirm the scientific data needed for improvement in probiotic products as current therapies. Five probiotic samples were collected from pharmaceutical companies available in the retail pharmacy, Rajshahi. The probiotic samples are tested before expiration dates as marked on manufacturer packages. The culture media used were Czapek Dox (pH 5.3), MRS and nutrient broth and agar for the investigation of lactic acid bacteria. The identified lactic acid bacteria (LAB) were lactobacillus acidophyllus (LAB 1), Lactobacillus bulgaricus (LAB 2), Lactococcus lactis (LAB 3) and Biffidobacterium biffidum (LAB 4) based on morphological characteristics, catalase activities, milk coagulation, carbohydrate fermentation profiles, resistance to antibiotics and other biochemical tests. The rejuvenation of probiotics particularly LAB from the probiotic samples can be used in other purposes such as biopreservation of lemon, orange juices with better tastes and fermented products like curds as well as hygienic qualities of other dairy products.

Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial.

BackgroundThe beneficial effect of probiotics on renal profile and liver function has been reported among patients with chronic kidney disease and fatty liver respectively. However, its effect on renal profile and liver function among type 2 diabetic individuals has not been fully understood. To investigate the effect of microbial cell preparation on renal profile and liver function tests among type 2 diabetic individuals.MethodsA randomized, double-blind, parallel-group, controlled clinical trial was conducted on a total of 136 type 2 diabetics age 30-70 years old in a teaching hospital in Kuala Lumpur, Malaysia. Subjects were randomly assigned to receive microbial cell preparation (N = 68) or a placebo (N = 68) for 12 weeks. The outcomes measured at baseline, week 6, and week 12 and included changes in renal profile (Sodium, Potassium, Urea, Creatinine, Glomerular Filtration Rate), and liver function tests (Albumin, Total Protein, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase). Intention to treat (ITT) analysis was performed on all the recruited subjects, while per protocol (PP) analysis was conducted on those who completed the trial with good compliance.ResultThe urea levels significantly declined in the probiotic group. Serum urea levels reduced from 4.26 mmol/L to 4.04 mmol/L in Probiotic Group while it increased in Placebo Group from 4.03 mmol/L to 4.24 mmol/L. These changes were significant between groups in ITT analysis (p = 0.018). Other parameters did not change significantly between groups.Conclusion12 weeks supplementation with daily dosage of 6 × 1010 Colony Forming Units of multi-strain microbial cell preparation significantly improved urea levels.Trial registration(Clinical trials: #NCT01752803)Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-015-0952-5) contains supplementary material, which is available to authorized users.

In vitro evidence for efficacy in food intolerance for the multispecies probiotic formulation Ecologic® Tolerance (Syngut™).

The beneficial effects of probiotics are currently the subject of extensive studies in health and medical research. The aim of this research was to specifically design a new probiotic formulation for supplementation in people suffering from food intolerance. The selection of strains was focussed on the capacity to influence mechanisms of action that are important in development of food intolerance with the following parameters measure: in vitro capacity to produce β-galactosidase, in vitro strengthening of the epithelial barrier, in vitro stimulation of cytokines produced by regulatory T cells, in addition to assessing fundamental quality criteria (stability, gastrointestinal (GI)-survival, multispecies concept, allergen-free). Ecologic®Tolerance/Syngut™ was subsequently developed consisting of a multispecies concept using 4 different probiotic strains (Bifidobacterium lactis W51, Lactobacillus acidophilus W22, Lactobacillus plantarum W21 and Lactococcus lactis W19). Each of these strains demonstrated ability to survive the GI-tract and strain specific effects in producing β-galactosidase, strengthening the gut barrier function after immunological-induced stress and inhibiting Th2 cytokines (IL-4, IL-5 and IL-13 (≥50%), in addition to stimulating interleukin-10 levels; thus, providing in vitro evidence for the efficacy of the selected strains to provide beneficial effects in patients suffering from food intolerance.

Longitudinal study of effects of oral dosage of Bifidobacterium bifidum G9-1 on Japanese cedar pollen-induced allergic nasal symptoms in guinea pigs.

Previous studies using experimental animal models have reported the beneficial effects of probiotics on allergic responses; however, their long-term effects on allergic nasal symptoms in clinical settings have not yet been elucidated in detail. In the present study, a guinea pig allergic rhinitis model involving repeated inhalation challenges with a natural allergen, Japanese cedar pollen, was used to examine the longitudinal effects of Bifidobacterium bifidum G9-1 (BBG9-1) on allergic nasal symptoms. BBG9-1 was administered orally once a day. Amelioration of nasal blockage was consistently observed throughout the experimental period in the BBG9-1-treated group. Although challenge-induced sneezing was not significantly inhibited in the BBG9-1-treated group, prolonged treatment with BBG9-1 slightly reduced the frequency of sneezing. Antigen-specific IgE antibody production was also not inhibited in the BBG9-1-treated group. Increases in the numbers of eosinophils and neutrophils in nasal cavity lavage fluid collected after pollen challenge were almost completely suppressed by BBG9-1 treatment, whereas those in mast cell mediators, histamine and cysteinyl leukotrienes were not. In contrast, increases in the levels of nitric oxide metabolites were potently suppressed. Furthermore, prolonged BBG9-1 treatment markedly suppressed exogenous leukotriene D4 -induced nasal blockage. Thus, prolonged oral administration of BBG9-1 suppresses Japanese cedar pollen-induced allergic nasal symptoms. The inhibitory mechanisms responsible may involve reductions in the responsiveness of target organs, such as endothelial cells in nasal mucosal blood vessels, to chemical mediators.

Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota.

The beneficial effects of probiotics are conditioned by their survival during passage through the human gastrointestinal tract and their ability to favorably influence gut microbiota. The main objective of this study was to use dynamic in vitro models of the human digestive tract to investigate the effect of fasted or fed state on the survival kinetics of the new probiotic Saccharomyces cerevisiae strain CNCM I-3856 and to assess its influence on intestinal microbiota composition and activity. The probiotic yeast showed a high survival rate in the upper gastrointestinal tract whatever the route of admistration, i.e., within a glass of water or a Western-type meal. S. cerevisiae CNCM I-3856 was more sensitive to colonic conditions, as the strain was not able to colonize within the bioreactor despite a twice daily administration. The main bacterial populations of the gut microbiota, as well as the production of short chain fatty acids were not influenced by the probiotic treatment. However, the effect of the probiotic on the gut microbiota was found to be individual dependent. This study shows that dynamic in vitro models can be advantageously used to provide useful insight into the behavior of probiotic strains in the human digestive environment.

Clinical Evidence of Effects of Lactobacillus plantarum HY7714 on Skin Aging: A Randomized, Double Blind, Placebo-Controlled Study.

The beneficial effects of probiotics are now widely reported, although there are only a few studies on their anti-aging effects. We have found that Lactobacillus plantarum HY7714 (HY7714) improves skin hydration and has anti-photoaging effects, and in the present study, we have further evaluated the anti-aging effect of HY7714 via a randomized, double blind, placebo-controlled clinical trial. The trial included 110 volunteers aged 41 and 59 years who have dry skin and wrinkles. Participants took 1 × 10(10) CFU/day of HY7714 (probiotic group) or a placebo (placebo group) for 12 weeks. Skin hydration, wrinkles, skin gloss, and skin elasticity were measured every 4 weeks during the study period. There were significant increases in the skin water content in the face (p < 0.01) and hands (p < 0.05) at week 12 in the probiotic group. Transepidermal water loss decreased significantly in both groups at weeks 4, 8, and 12 (p < 0.001 compared with baseline), and was suppressed to a greater extent in the face and forearm in the probiotic group at week 12. Volunteers in the probiotic group had a significant reduction in wrinkle depth at week 12, and skin gloss was also significantly improved by week 12. Finally, skin elasticity in the probiotic group improved by 13.17% (p < 0.05 vs. controls) after 4 weeks and by 21.73% (p < 0.01 vs. controls) after 12 weeks. These findings are preliminary confirmation of the anti-aging benefit to the skin of L. plantarum HY7714 as a nutricosmetic agent.

Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children.

Recent studies have suggested some beneficial effects of probiotics and/or prebiotics on obesity in adults; such experience is limited in children and adolescents. This study was an open-label, randomised, controlled study including children with primary obesity. The first group was treated with a standard method with a reduced calorie intake and increased physical activity. The second group received add-on daily synbiotic supplementation during one month. The aim of this study was to evaluate potential effects of a synbiotic on anthropometric measurements, lipid profile and oxidative stress parameters. One month of supplementation of the synbiotic resulted in a significant reduction of weight (P<0.001) and body mass index (P<0.01). Changes (% reduction comparing to baseline) in anthropometric measurements, were significantly higher in the children receiving the additional synbiotic supplement (P<0.05). The percentage of children with weight loss was higher in the synbiotic group, but not statistically significant (71.4 vs 64.2%, P>0.05). At the 30(th) day of synbiotic intervention, serum total cholesterol, low density lipoprotein cholesterol and total oxidative stress levels significantly declined (P<0.05). Changes in serum lipid levels were significantly higher in the synbiotic group (P<0.05). Changes in serum total oxidative stress levels before and after the intervention period, were significant in synbiotic group (P<0.01). In our study, changes in weight, body mass index, and triceps skinfold thickness were higher in the group receiving the one month synbiotic supplement thin in the standard method group. The supplement tested also had a beneficial effect on lipid profile and total oxidative stress. To the best of our knowledge, this is the first study showing the effects of synbiotics on oxidative stress in obese patients with an additional effect on weight loss regarding to previous studies.

Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease.

Inflammatory bowel disease (IBD) is a group of diseases characterized by inflammation of the small and large intestine and primarily includes ulcerative colitis and Crohn's disease. Although the etiology of IBD is not fully understood, it is believed to result from the interaction of genetic, immunological, and environmental factors, including gut microbiota. Recent studies have shown a correlation between changes in the composition of the intestinal microbiota and IBD. Moreover, it has been suggested that probiotics and prebiotics influence the balance of beneficial and detrimental bacterial species, and thereby determine homeostasis versus inflammatory conditions. In this review, we focus on recent advances in the understanding of the role of prebiotics, probiotics, and synbiotics in functions of the gastrointestinal tract and the induction and maintenance of IBD remission. We also discuss the role of psychobiotics, which constitute a novel class of psychotropic agents that affect the central nervous system by influencing gut microbiota.

New perspectives on probiotics in health and disease

The gut microbiota continues to fascinate scientists in many realms when it is considered that humans contain 90% bacteria. Correlations between changes in composition and activity of the gut microbiota and common disorders such as cancer, hypertension, hypercholesterolemia, inflammatory bowel diseases, obesity, oral health, etc. have been proposed. What is the real role of probiotics, prebiotics and synbiotics in influencing a healthy microbiota? Both in vitro evidences and in vivo clinical data have supported some of these new health claims, while recent molecular advancement has provided strong indications to support and justify the hypotheses. However, probiotics validity and health claims have continuously been rejected on the basis of “biomarker deficiency”. To battle the increase in health care costs, a preventive approach to medicine with the development of probiotics and prebiotics or symbiotic products is being advanced. This review discusses the potential beneficial effects of probiotics in preventing and treating certain diseases as well as current and future perspectives of probiotic research.

Metabolites produced during the growth of probiotics in cocoa supplementation and the limited role of cocoa in host-enteric bacterial pathogen interactions

Cocoa contains various compounds that can significantly affect the growth of a broad range of bacteria, and have multiple human health-promoting properties. In this study, the effects of cocoa powder on the growth of Lactobacillus, common milk resident bacteria, and three major foodborne enteric bacterial pathogens; enterohemorrhagic Escherichia coli O157:H7 (EHEC), Salmonella enterica serovar Typhimurium, and Listeria monocytogenes, were investigated in vitro. Significant (p < 0.05) growth stimulation on beneficial bacteria including Lactobacillus and other resident bacteria in milk was observed in the presence of 3% cocoa powder. In contrast, growth of three foodborne enteric pathogens was significantly (p < 0.05) inhibited within 9 h, but no stimulation was found with longer incubation. In addition, cocoa powder significantly (p < 0.05) inhibited adhesion to and invasion of INT407 cells by these bacterial pathogens in a dose dependent manner. These results suggest that addition of cocoa into dairy products could improve the beneficial effect of probiotics by stimulating their growth, without raising the risk of cross-contamination with enteric pathogens.

Omnipresence of Probiotics in Diversified Clinical Practices

As reviewed in details about the bidirectional relationship between the positive influence of probiotics and wellness of humans. Beneficial effects of probiotics in the present scenario are recently developed very popular due to its therapeutics responsible for human health in different diseased conditions. Despite the globally popularity of health benefits of probiotics, there is only very little information available on the advantages and application of probiotics. According to the National Centre for Complementary and Alternative Medicine in connection with the American Society for Microbiology and FAO/WHO focused on account beneficial effects of probiotics in different diseased conditions of patients because of its unconstrained power in the treatment of various diseases and disorders especially gastro intestinal and cancer diseases. On the basis of accumulating data available on literature have strongly linked with human health. Hence, the present review reflected on an overview on the use of probiotics organisms as live supplements, with specific importance on Lactobacillus acidophilus and Bifidobacterium spp. Increasing knowledge on probiotics is delighting, but in the near future it must be specified that which probiotics are most effective in specific diseases conditions. Well-designed, randomized clinical trials are still required to further define the role of probiotics as preventive and therapeutic agents. The purpose of this review is to give current state of awareness about probiotics and their influence on our well-being.

Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

To investigate the efficacy of probiotics in irritable bowel syndrome (IBS) patients. PubMed, Cochrane library, Scopus, Google Scholar, and Clinicaltrial.gov databases were searched for literature published between September 2007 and December 2013. The applied Mesh terms were "probiotics," "irritable bowel syndrome," and "irritable bowel syndrome treatment." The collected data contained24 clinical trials, of which 15 were eligible for meta-analysis and nine were reviewed systematically. All studies were randomized placebo-controlled trials in patients with IBS that investigated the efficacy of probiotics in IBS improvement. The Jadad score was used to assess the methodological quality of trials. The quality scale ranges from 0 to 5 points, with a score ≤ 2 indicating a low quality report, and a score of ≥ 3 indicating a high quality report. Relative risk (RR), standardized effect size, and 95%CI were calculated using the DerSimonian-Laird method. The Cochran Q test was used to test heterogeneity with P < 0.05. Funnel plots were constructed and Egger's and Begg-Mazumdar tests were performed to assess publication bias. A total of 1793 patients were included in the meta-analysis. The RR of responders to therapies based on abdominal pain score in IBS patients for two included trials comparing probiotics to placebo was 1.96 (95%CI: 1.14-3.36; P = 0.01). RR of responders to therapies based on a global symptom score in IBS patients for two included trials comparing probiotics with placebo was 2.43 (95%CI: 1.13-5.21; P = 0.02). For adequate improvement of general symptoms in IBS patients, the RR of seven included trials (six studies) comparing probiotics with placebo was 2.14 (95%CI: 1.08-4.26; P = 0.03). Distension, bloating, and flatulence were evaluated using an IBS severity scoring system in three trials (two studies) to compare the effect of probiotic therapy in IBS patients with placebo, the standardized effect size of mean differences for probiotics therapy was -2.57 (95%CI: -13.05--7.92). Probiotics reduce pain and symptom severity scores. The results demonstrate the beneficial effects of probiotics in IBS patients in comparison with placebo.

The effects of probiotic supplementation on lean body mass, strength, and power, and health indicators in resistance trained males: a pilot study

Background While growing evidence suggests beneficial effects of probiotics on the gut-brain-axis, only a limited number of studies have investigated the impact of gut microbiota modulation on muscle physiology (gut-muscle-axis). The probiotic BC30 (Ganeden Biotech Inc., Maryfield Heights, OH) has been shown to increase protein absorption and the anabolic potential of a respective protein source has been directly linked to peak plasma leucine levels. Postworkout administration of slow digesting proteins such as casein show inferior results on muscle protein synthesis in comparison to fast absorbed proteins such as whey. Thus, the purpose of this investigation was to determine if the co-administration of a probiotic with a slow digested protein has a beneficial effect on body composition, performance, and measures of perceived health. Methods 10 healthy resistance-trained individuals volunteered to participate in this study (mean+/-SD; age: 22.0 ± 2.4 yr; height: 181.8 ± 4.1 cm; weight: 85.6 ± 12.9 kg). Subjects were randomly assigned to consume either 20g of casein (Control = CON) or 20g of casein plus probiotic (500M BC30, =BC30) twice daily. Subjects were instructed to consume one serving in the morning upon waking while the second serving was consumed after training or before bed on non-training days. With assistance from a dietician, macronutrients were controlled to 50% carbohydrate, 25% protein, and 25% fat between groups using the Mifflin-St Jeor formula. Subjects performed full body workouts 4-times per week for 8 weeks consisting of hypertrophy (8-12 RM loads and 60 seconds rest), and strength (1-5 RM loads with 3-5 minutes rest) under supervision of the researchers in order to ensure compliance. Body composition (Dual X-Ray Absorptiometry; DXA), quadriceps thickness (ultrasound), peak power (Monark Wingate Cycle), vertical jump power (Tendo unit), 1-RM bench press, and 1-RM leg press were measured at baseline and after the eighth week of supplementation. Perceived GI health (GSRS) was measured weekly and upper respiratory health (WURSS-21) daily. Consent to publish the results was obtained from all participants.

Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.

Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung's disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease-associated enterocolitis (HAEC). We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4weeks. In next 3months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA). Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group. Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with ClinicalTrials.gov, NCT number: NCT01934959).

Postbiotic activities of lactobacilli-derived factors.

Probiotics are alive nonpathogenic microorganisms present in the gut microbiota that confer benefits to the host for his health. They act through molecular and cellular mechanisms that contrast pathogen bacteria adhesion, enhance innate immunity, decrease pathogen-induced inflammation, and promote intestinal epithelial cell survival, barrier function, and protective responses. Some of these beneficial effects result to be determined by secreted probiotic-derived factors that recently have been identified as "postbiotic" mediators. They have been reported for several probiotic strains but most available literature concerns Lactobacilli. In this review, we focus on the reported actions of several secretory products of different Lactobacillus species highlighting the available mechanistic data. The identification of soluble factors mediating the beneficial effects of probiotics may present an opportunity not only to understand their fine mechanisms of action, but also to develop effective pharmacological strategies that could integrate the action of treatments with live bacteria.